Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEAZD4320Cat.No.:HY-112416CASNo.:1357576-48-7分?式:C??H??ClF?N?O?S?分?量:945.53作?靶點(diǎn):Bcl-2Family作?通路:Apoptosis儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:125mg/mL(132.20mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.0576mL5.2880mL10.5761mL5mM0.2115mL1.0576mL2.1152mL10mM0.1058mL0.5288mL1.0576mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時(shí)，請?jiān)?個(gè)?內(nèi)使?，-20°C儲存時(shí)，請?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥6.25mg/mL(6.61mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性AZD4320BH-3的新型類似物，有效的BCL2/BCLxL的雙重抑制劑。AZD4320對于KPUM-MS3，KPUM-UH1，和STR-428細(xì)胞系的IC50分別為26nM，17nM，和170nM。IC50&TargetBCL2BCLxL17nM(IC50,KPUM-UH1cells)17nM(IC50,KPUM-UH1cells)體外研究AZD4320potentlyaugmentstheantitumoreffectofAZD5153(Cat.No.:HY-100653A)indoubleexpressinglymphoma(DEL)-anddoublehitlymphoma(DHL)-derivedcelllinesinadose-dependentmanner.AZD4320showsmostlysynergistic,andatleastadditive,growthinhibitoryeffectsonDEL-andDHLderivedcelllines,andprofoundlyincreasescellsundergoingapoptosisinallthreecelllines[1].PROTOCOLCellAssay[1]TwoDEL-derivedcelllines,KPUM-MS3andKPUM-UH1,andaDHL-derivedcellline,STR-428areused.ToexaminethecombinatorygrowthinhibitoryeffectsofAZD4320,cellsaretreatedwithfiveconcentrations(0.25,0.5,1.0,2.0,4.0×IC50)for72h,andsubjectedtoamodifiedMTTassay[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.REFERENCES[1].Takimoto-ShimomuraT,etal.Dualtargetingofbromodomain-containing4byAZD5153andBCL2byAZD4320againstB-celllymphomasconcomitantlyoverexpressingc-MYCandBCL2.InvestNewDrugs.2018Jun21.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuse